China Approves First Hemophilia B Gene Therapy: BBM-H901 Shows Promising Results in Single-Dose Treatment

The National Medical Products Administration (搜索)搜索该词条 (NMPA) has officially approved BBM-H901查看药品详情 (Dalnacogene Ponparvovec Injection (搜索)搜索该药品) for the treatment of adult patients with moderate to severe hemophilia B (搜索)搜索该疾病, marking a significant breakthrough in gene therapy for this rare bleeding disorder in China. Developed by Belief BioMed (搜索)搜索该词条 (BBM) and to be commercialized by Takeda China (搜索)搜索该词条, this innovative treatment represents the first approved hemophilia B gene therapy in the country.

Transformative Treatment for Hemophilia B Patients

Hemophilia B (搜索)搜索该疾病, an inherited bleeding disorder caused by factor IX查看药品详情 (FIX (搜索)搜索该靶点) deficiency, affects approximately 1 in 30,000 male births globally. Until now, Chinese patients have relied primarily on prothrombin complex concentrate (PCC) or FIX replacement therapy, requiring frequent intravenous injections that create substantial physical, emotional, and financial burdens.

BBM-H901查看药品详情 works through a fundamentally different mechanism than traditional treatments. The therapy utilizes a recombinant adeno-associated virus (rAAV) vector to deliver an optimized human coagulation FIX (搜索)搜索该靶点 gene directly into patients' liver cells. These cells then continuously express and secrete coagulation FIX into the bloodstream, promoting normal clotting function with just a single administration.

Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of BBM, emphasized the significance of this approval: "The approval of BBM-H901查看药品详情 is an important milestone in the development of BBM. As the first hemophilia B (搜索)搜索该疾病 gene therapy drug independently developed in China, BBM-H901 will provide a new treatment option for hemophilia B patients, which is expected to provide patients with an innovative treatment solution and help them return to a normal life."

Impressive Clinical Results

The Phase III clinical trial results, presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in December 2024, demonstrated remarkable efficacy. After 52 weeks of follow-up:

• Mean annualized bleeding rate (ABR) was reduced to just 0.6
• Average FIX activity reached 55.08 IU/dL (one Stage Assay SynthaSIL aPTT reagent)
• Average number of FIX infusions decreased from 58.2 times/year to only 2.9 times/year
• 80.8% of participants (21 of 26) experienced no bleeding events after treatment
• No serious adverse events were reported

Professor Zhang Lei from the Blood Disease Hospital of the Chinese Academy of Medical Sciences, who led the registered clinical study, described the approval as bringing "revolutionary hope" to Chinese hemophilia B (搜索)搜索该疾病 patients. "By a single dosing, the risk of bleeding and joint damage can be reduced, and patients are back to a normal life," he stated.

Earlier investigator-initiated trials also showed promising results. A study published in The Lancet-Hematology and The New England Journal of Medicine in 2022 demonstrated that ten adult patients with moderate to severe hemophilia B (搜索)搜索该疾病 achieved a mean FIX (搜索)搜索该靶点 activity of 36.9 IU/dL after a median follow-up of 58 weeks, with no serious adverse events reported. Long-term follow-up data presented at the 2024 International Society on Thrombosis and Haemostasis (ISTH) Congress confirmed that FIX activity remained stable over three years, with no drug-related serious adverse events, thrombotic events, or inhibitors observed.

Strategic Partnership for Commercialization

The collaboration between Belief BioMed (搜索)搜索该词条 and Takeda China (搜索)搜索该词条 aims to accelerate patient access to this breakthrough therapy. BBM will handle development and manufacturing, while Takeda China will manage commercialization across mainland China, Hong Kong, and Macau.

Sean Shan, Senior Vice President of Takeda Pharmaceutical and President of Takeda China (搜索)搜索该词条, highlighted the strategic importance of this partnership: "The approval of BBM-H901查看药品详情 will further enrich our portfolio in hemophilia and rare disease areas, and will help more patients to benefit from innovative treatments. In the future, Takeda China will continue to deepen our strategic cooperation with local partners, to accelerate the commercialization of more breakthrough therapies."

Regulatory Recognition and Future Prospects

BBM-H901查看药品详情 has received significant regulatory recognition beyond China. The therapy has obtained Breakthrough Therapy Designation from China's Center for Drug Evaluation, Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), Rare Pediatric Disease Designation from the FDA, and Advanced Therapy Medical Products designation from the European Medicines Agency (EMA).

These designations reflect the potential global impact of this therapy and may accelerate its availability to hemophilia B (搜索)搜索该疾病 patients worldwide. BBM has expressed intentions to pursue overseas commercialization to benefit more patients globally.

Advancing Gene Therapy in China

This approval represents a milestone not only for hemophilia B (搜索)搜索该疾病 treatment but also for China's growing gene therapy sector. As one of the first domestically developed gene therapies to receive regulatory approval in China, BBM-H901查看药品详情 demonstrates the country's increasing capabilities in advanced biopharmaceutical research and development.

For patients with hemophilia B (搜索)搜索该疾病, the approval offers hope for a dramatically improved quality of life with reduced bleeding episodes, fewer hospital visits, and potentially normal daily activities without the constant fear of bleeding events that can cause long-term joint damage.

The continuous follow-up of clinical trial participants will provide additional insights into the long-term safety and efficacy of this groundbreaking treatment, potentially establishing a new standard of care for hemophilia B (搜索)搜索该疾病 management in China and beyond.